|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ,
Meester RGS, Barzi A and Jemal A: Colorectal cancer statistics,
2017. CA Cancer J Clin. 67:177–193. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jass JR: Classification of colorectal
canfcer based on correlation of clinical, morphological and
molecular features. Histopathology. 50:113–130. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pino MS and Chung DC: The chromosomal
instability pathway in colon cancer. Gastroenterology.
138:2059–2072. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Leggett B and Whitehall V: Role of the
serrated pathway in colorectal cancer pathogenesis.
Gastroenterology. 138:2088–2100. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rex DK, Ahnen DJ, Baron JA, Batts KP,
Burke CA, Burt RW, Goldblum JR, Guillem JG, Kahi CJ, Kalady MF, et
al: Serrated lesions of the colorectum: Review and recommendations
from an expert panel. Am J Gastroenterol. 107:1315–1329. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Worthley DL and Leggett BA: Colorectal
cancer: Molecular features and clinical opportunities. Clin Biochem
Rev. 31:31–38. 2010.PubMed/NCBI
|
|
8
|
McCubrey JA, Steelman LS, Abrams SL, Lee
JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA,
D'Assoro AB, et al: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT
pathways in malignant transformation and drug resistance. Adv
Enzyme Regul. 46:249–279. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Van Cutsem E, Köhne CH, Láng I, Folprecht
G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D,
Tejpar S, et al: Cetuximab plus irinotecan, fluorouracil, and
leucovorin as first-line treatment for metastatic colorectal
cancer: Updated analysis of overall survival according to tumor
KRAS and BRAF mutation status. J Clin Oncol. 29:2011–2019. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Modest DP, Ricard I, Heinemann V,
Hegewisch-Becker S, Schmiegel W, Porschen R, Stintzing S, Graeven
U, Arnold D, von Weikersthal LF, et al: Outcome according to KRAS-,
NRAS- and BRAF-mutation as well as KRAS mutation variants: Pooled
analysis of five randomized trials in metastatic colorectal cancer
by the AIO colorectal cancer study group. Ann Oncol. 27:1746–1753.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Andreatos N, Ronnekleiv-Kelly S, Margonis
GA, Sasaki K, Gani F, Amini N, Wilson A and Pawlik TM: From bench
to bedside: Clinical implications of KRAS status in patients with
colorectal liver metastasis. Surg Oncol. 25:332–338. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lujambio A and Lowe SW: The microcosmos of
cancer. Nature. 482:347–355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rusek AM, Abba M, Eljaszewicz A, Moniuszko
M, Niklinski J and Allgayer H: MicroRNA modulators of epigenetic
regulation, the tumor microenvironment and the immune system in
lung cancer. Mol Cancer. 14:342015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee SC, Tan HT and Chung MC: Prognostic
biomarkers for prediction of recurrence of hepatocellular
carcinoma: Current status and future prospects. World J
Gastroenterol. 20:3112–3124. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu Y, Chen X, Cheng R, Yang F, Yu M, Wang
C, Cui S, Hong Y, Liang H, Liu M, et al: The Jun/miR-22/HuR
regulatory axis contributes to tumourigenesis in colorectal cancer.
Mol Cancer. 17:112018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chai J, Guo D, Ma W, Han D, Dong W, Guo H
and Zhang Y: A feedback loop consisting of
RUNX2/LncRNA-PVT1/miR-455 is involved in the progression of
colorectal cancer. Am J Cancer Res. 8:538–550. 2018.PubMed/NCBI
|
|
18
|
Huang L, Cai JL, Huang PZ, Kang L, Huang
MJ, Wang L and Wang JP: miR19b-3p promotes the growth and
metastasis of colorectal cancer via directly targeting ITGB8. Am J
Cancer Res. 7:1996–2008. 2017.PubMed/NCBI
|
|
19
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schetter AJ, Okayama H and Harris CC: The
role of microRNAs in colorectal cancer. Cancer J. 18:244–252. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Baraniskin A, Birkenkamp-Demtroder K,
Maghnouj A, Zöllner H, Munding J, Klein-Scory S, Reinacher-Schick
A, Schwarte-Waldhoff I, Schmiegel W and Hahn SA: miR-30a-5p
suppresses tumor growth in colon carcinoma by targeting DTL.
Carcinogenesis. 33:732–739. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Braun CJ, Zhang X, Savelyeva I, Wolff S,
Moll UM, Schepeler T, Ørntoft TF, Andersen CL and Dobbelstein M:
p53-responsive micrornas 192 and 215 are capable of inducing cell
cycle arrest. Cancer Res. 68:10094–10104. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang H, Cao F, Li X, Miao H, E J, Xing J
and Fu CG: miR-320b suppresses cell proliferation by targeting
c-Myc in human colorectal cancer cells. BMC Cancer. 15:7482015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
O'Donnell KA, Wentzel EA, Zeller KI, Dang
CV and Mendell JT: c-Myc-regulated microRNAs modulate E2F1
expression. Nature. 435:839–843. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Johnson SM, Grosshans H, Shingara J, Byrom
M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D and Slack
FJ: RAS is regulated by the let-7 microRNA family. Cell.
120:635–647. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Forzati F, De Martino M, Esposito F, Sepe
R, Pellecchia S, Malapelle U, Pellino G, Arra C and Fusco A:
miR-155 is positively regulated by CBX7 in mouse embryonic
fibroblasts and colon carcinomas, and targets the KRAS oncogene.
BMC Cancer. 17:1702017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lagos-Quintana M, Rauhut R, Yalcin A,
Meyer J, Lendeckel W and Tuschl T: Identification of
tissue-specific microRNAs from mouse. Curr Biol. 12:735–739. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Michael MZ, O'Connor SM, van Holst
Pellekaan NG, Young GP and James RJ: Reduced accumulation of
specific microRNAs in colorectal neoplasia. Mol Cancer Res.
1:882–891. 2003.PubMed/NCBI
|
|
29
|
Akao Y, Nakagawa Y and Naoe T:
MicroRNA-143 and −145 in colon cancer. DNA Cell Biol. 26:311–320.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ng EK, Tsang WP, Ng SS, Jin HC, Yu J, Li
JJ, Röcken C, Ebert MP, Kwok TT and Sung JJ: MicroRNA-143 targets
DNA methyltransferases 3A in colorectal cancer. Br J Cancer.
101:699–706. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Esau C, Kang X, Peralta E, Hanson E,
Marcusson EG, Ravichandran LV, Sun Y, Koo S, Perera RJ, Jain R, et
al: MicroRNA-143 regulates adipocyte differentiation. J Biol Chem.
279:52361–52365. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lewis BP, Shih IH, Jones-Rhoades MW,
Bartel DP and Burge CB: Prediction of mammalian microRNA targets.
Cell. 115:787–798. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Griffiths-Jones S, Grocock RJ, van Dongen
S, Bateman A and Enright AJ: miRBase: microRNA sequences, targets
and gene nomenclature. Nucleic Acids Res 34 (Database Issue).
D140–D144. 2006. View Article : Google Scholar
|
|
35
|
Eslamizadeh S, Heidari M, Agah S,
Faghihloo E, Ghazi H, Mirzaei A and Akbari A: The role of microRNA
signature as diagnostic biomarkers in different clinical stages of
colorectal cancer. Cell J. 20:220–230. 2018.PubMed/NCBI
|
|
36
|
Wang CJ, Zhou ZG, Wang L, Yang L, Zhou B,
Gu J, Chen HY and Sun XF: Clinicopathological significance of
microRNA-31, −143 and −145 expression in colorectal cancer. Dis
Markers. 26:27–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ahmad I, Singh LB, Yang ZH, Kalna G,
Fleming J, Fisher G, Cooper C, Cuzick J, Berney DM, Møller H, et
al: Mir143 expression inversely correlates with nuclear ERK5
immunoreactivity in clinical prostate cancer. Br J Cancer.
108:149–154. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shen JZ, Zhang YY, Fu HY, Wu DS and Zhou
HR: Overexpression of microRNA-143 inhibits growth and induces
apoptosis in human leukemia cells. Oncol Rep. 31:2035–2042. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Johannessen C, Moi L, Kiselev Y, Pedersen
MI, Dalen SM, Braaten T and Busund LT: Expression and function of
the miR-143/145 cluster in vitro and in vivo in human breast
cancer. PLoS One. 12:e01866582017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pichler M, Winter E, Stotz M, Eberhard K,
Samonigg H, Lax S and Hoefler G: Down-regulation of
KRAS-interacting miRNA-143 predicts poor prognosis but not response
to EGFR-targeted agents in colorectal cancer. Br J Cancer.
106:1826–1832. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Friday BB and Adjei AA: K-ras as a target
for cancer therapy. Biochim Biophys Acta. 1756:127–144.
2005.PubMed/NCBI
|
|
42
|
Forrester K, Almoguera C, Han K, Grizzle
WE and Perucho M: Detection of high incidence of K-ras oncogenes
during human colon tumorigenesis. Nature. 327:298–303. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Haliassos A, Chomel JC, Grandjouan S, Kruh
J, Kaplan JC and Kitzis A: Detection of minority point mutations by
modified PCR technique: A new approach for a sensitive diagnosis of
tumor-progression markers. Nucleic Acids Res. 17:8093–8099. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Brummelkamp TR, Bernards R and Agami R:
Stable suppression of tumorigenicity by virus-mediated RNA
interference. Cancer Cell. 2:243–247. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Smakman N, Veenendaal LM, van Diest P, Bos
R, Offringa R, Borel Rinkes IH and Kranenburg O: Dual effect of
Kras(D12) knockdown on tumorigenesis: Increased immune-mediated
tumor clearance and abrogation of tumor malignancy. Oncogene.
24:8338–8342. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Su J, Liang H, Yao W, Wang N, Zhang S, Yan
X, Feng H, Pang W, Wang Y, Wang X, et al: miR-143 and miR-145
regulate IGF1R to suppress cell proliferation in colorectal cancer.
PLoS One. 9:e1144202014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hsu SD, Lin FM, Wu WY, Liang C, Huang WC,
Chan WL, Tsai WT, Chen GZ, Lee CJ, Chiu CM, et al: miRTarBase: A
database curates experimentally validated microRNA-target
interactions. Nucleic Acids Res 39 (Database issue). D163–D169.
2011. View Article : Google Scholar
|
